Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Change in Accured Expenses: 2020-2025

Historic Change in Accured Expenses for Tango Therapeutics (TNGX) over the last 5 years, with Sep 2025 value amounting to $1.6 million.

  • Tango Therapeutics' Change in Accured Expenses rose 190.72% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 million, marking a year-over-year decrease of 152.01%. This contributed to the annual value of $1.1 million for FY2024, which is 155.89% up from last year.
  • Tango Therapeutics' Change in Accured Expenses amounted to $1.6 million in Q3 2025, which was up 41.20% from $1.1 million recorded in Q2 2025.
  • Tango Therapeutics' 5-year Change in Accured Expenses high stood at $4.4 million for Q2 2022, and its period low was -$6.7 million during Q1 2023.
  • Its 3-year average for Change in Accured Expenses is -$389,000, with a median of $1.1 million in 2025.
  • In the last 5 years, Tango Therapeutics' Change in Accured Expenses soared by 88,020.16% in 2021 and then crashed by 4,169.43% in 2023.
  • Tango Therapeutics' Change in Accured Expenses (Quarterly) stood at $35,000 in 2021, then spiked by 4,985.71% to $1.8 million in 2022, then soared by 124.55% to $4.0 million in 2023, then crashed by 62.70% to $1.5 million in 2024, then surged by 190.72% to $1.6 million in 2025.
  • Its Change in Accured Expenses stands at $1.6 million for Q3 2025, versus $1.1 million for Q2 2025 and -$6.1 million for Q1 2025.